Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Purchased by PDT Partners LLC

PDT Partners LLC lifted its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 188.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 113,712 shares of the company’s stock after purchasing an additional 74,349 shares during the quarter. PDT Partners LLC owned about 0.24% of Mirum Pharmaceuticals worth $4,435,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Rice Hall James & Associates LLC raised its holdings in shares of Mirum Pharmaceuticals by 6.9% in the second quarter. Rice Hall James & Associates LLC now owns 229,730 shares of the company’s stock worth $7,854,000 after buying an additional 14,843 shares during the last quarter. Candriam S.C.A. purchased a new position in Mirum Pharmaceuticals in the 2nd quarter worth $17,384,000. Hennion & Walsh Asset Management Inc. raised its stake in Mirum Pharmaceuticals by 64.9% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 104,770 shares of the company’s stock worth $3,582,000 after acquiring an additional 41,236 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Mirum Pharmaceuticals by 48.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 143,000 shares of the company’s stock worth $4,889,000 after acquiring an additional 46,506 shares during the period. Finally, GSA Capital Partners LLP grew its stake in Mirum Pharmaceuticals by 791.7% during the 3rd quarter. GSA Capital Partners LLP now owns 57,985 shares of the company’s stock valued at $2,261,000 after purchasing an additional 51,482 shares during the last quarter.

Insider Activity

In related news, SVP Jolanda Howe sold 2,500 shares of the company’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $47.10, for a total transaction of $117,750.00. Following the completion of the transaction, the senior vice president now owns 2,426 shares in the company, valued at $114,264.60. This represents a 50.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals Trading Down 0.9 %

MIRM stock opened at $46.22 on Friday. Mirum Pharmaceuticals, Inc. has a 52-week low of $23.14 and a 52-week high of $48.89. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. The firm has a market cap of $2.22 billion, a P/E ratio of -22.88 and a beta of 1.16. The company’s 50-day simple moving average is $40.93 and its 200-day simple moving average is $37.31.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $90.38 million for the quarter, compared to the consensus estimate of $81.99 million. During the same quarter in the prior year, the business posted ($0.57) earnings per share. Mirum Pharmaceuticals’s revenue for the quarter was up 89.4% on a year-over-year basis. As a group, equities analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.48 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Evercore ISI raised their price objective on Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. HC Wainwright restated a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Robert W. Baird upped their price objective on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Cantor Fitzgerald raised their target price on shares of Mirum Pharmaceuticals from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. Finally, Citigroup upped their price target on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $57.73.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.